# Pipeline Change Report — Johnson & Johnson

- Run date (UTC): 2026-01-07
- Source: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Extracted 'as of' date: October 14, 2025
- Confidence score (0–1): 0.55

- Extracted program count: 105

## New / Added items
- **AKEEGA (niraparib/abiraterone)** — Partner: TESARO, an oncology-focused business within GSK
- **Bleximenib** — Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine — Trial/Program: cAMeLot-2
- **bleximenib** — Relapsed Refractory Acute Myeloid Leukemia — Trial/Program: ALE1001
- **CABENUVA** — HIV Adolescents — Partner: ViiV Healthcare
- **CAPLYTA (lumateperone)** — Adjunctive Treatment for Major Depressive Disorder
- **CAPLYTA (lumateperone)** — Bipolar Mania
- **CAPLYTA (lumateperone)** — Pediatric Psychiatric Indications
- **CARVYKTI (Ciltacabtagene autoleucel)** — Frontline Multiple Myeloma TNI — Trial/Program: CARTITUDE-5 — Partner: Legend Biotech
- **CARVYKTI (Ciltacabtagene autoleucel)** — Frontline Multiple Myeloma Transplant Eligible vs ASCT — Trial/Program: CARTITUDE-6 — Partner: Legend Biotech
- **DARZALEX (daratumumab)** — Frontline multiple myeloma transplant ineligible — Trial/Program: CEPHEUS — Partner: Genmab A/S
- **DARZALEX (daratumumab)** — M1 Metastatic Castration-Sensitive Prostate Cancer — Trial/Program: AMPLITUDE — Partner: Genmab A/S
- **DARZALEX (daratumumab)** — Smoldering Multiple Myeloma — Trial/Program: AQUILA — Partner: Genmab A/S
- **ERLEADA (apalutamide)** — High Risk Prostate Cancer — Trial/Program: PROTEUS — Partner: Regents of California and Memorial Sload Kettering
- **ERLEADA (apalutamide)** — Localized Prostate Cancer — Trial/Program: ATLAS — Partner: Regents of California and Memorial Sload Kettering
- **icotrokinra** — Pediatric Crohn's Disease — Trial/Program: MACARONI-23
- **icotrokinra** — Pediatric Juvenile Psoriatic Arthritis
- **icotrokinra** — Pediatric Ulcerative Colitis — Trial/Program: QUASAR JR
- **icotrokinra** — Psoriasis — Trial/Program: ICONIC
- **icotrokinra** — Psoriatic Arthritis
- **icotrokinra** — Psoriatic Arthritis Structural Damage — Trial/Program: APEX
- **icotrokinra** — Ulcerative Colitis
- **icotrokinra** — Ulcerative Colitis Subcutaneous Induction — Trial/Program: ASTRO
- **IMAAVY (nipocalimab)** — Generalized Myasthenia Gravis — Trial/Program: Vivacity MG3
- **IMAAVY (nipocalimab)** — Generalized Myasthenia Gravis Pediatrics — Trial/Program: VIBRANCE MG
- **IMBRUVICA (ibrutinib)** — Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) — Trial/Program: GLOW — Partner: Pharmacyclics, LLC, an AbbVie company
- **IMBRUVICA (ibrutinib)** — Frontline Mantle Cell Lymphoma — Trial/Program: Triangle — Partner: Pharmacyclics, LLC, an AbbVie company
- **INLEXZO (gemcitabine intravesical system)** — High Risk Non Muscle Invasive Bladder Cancer BGC Experienced — Trial/Program: SunRISe-5
- **INLEXZO (gemcitabine intravesical system)** — Non Muscle Invasive Bladder Cancer — Trial/Program: SunRISe-1
- **INLEXZO (gemcitabine intravesical system)** — Non Muscle Invasive Bladder Cancer BCG-naïve High Risk — Trial/Program: SunRISe-3
- **ITI-1284** — Alzheimer's Disease-Related Agitation
- **ITI-1284** — Alzheimer's Disease-Related Psychosis
- **ITI-1284** — Generalized Anxiety Disorder
- **JNJ-0387** — Solid Tumors
- **JNJ-0631 (ARX305)** — Renal Cancer
- **JNJ-0683 (ARX788)** — Breast Cancer
- **JNJ-1493** — Hematological Malignancies
- **JNJ-1887** — Geographic Atrophy — Partner: Hemera Biosciences
- **JNJ-1900** — Head and Neck Cancer — Partner: Nanobiotix
- **JNJ-1900** — Lung Cancer — Partner: Nanobiotix
- **JNJ-2056** — Alzheimer's Disease — Trial/Program: RETAIN — Partner: AC Immune SA
- **JNJ-2638** — Gastrointestinal Cancer
- **JNJ-2761** — Multiple Myeloma
- **JNJ-3413** — Lymphoma
- **JNJ-4496** — Hematological Malignancies
- **JNJ-4680** — Lung Cancer
- **JNJ-4681** — Hematological Malignancies
- **JNJ-4804 Co-antibody Therapy** — Crohn's Disease
- **JNJ-4804 Co-antibody Therapy** — Psoriatic Arthritis
- **JNJ-4804 Co-antibody Therapy** — Ulcerative Colitis
- **JNJ-4916** — Lung Cancer
- **JNJ-5108** — Immunological Diseases
- **JNJ-5120** — Major Depressive Disorder
- **JNJ-5322** — Multiple Myeloma
- **JNJ-5939** — Atopic Dermatitis
- **JNJ-6420** — Prostate Cancer
- **JNJ-6848** — Immunological Diseases
- **JNJ-7446** — Lung Cancer
- **JNJ-7528** — Atopic Dermatitis
- **JNJ-8177 (ARX517)** — Prostate Cancer
- **JNJ-8377** — Lymphoma
- **JNJ-8543** — Hematological Malignancies
- **JNJ-9401** — Prostate Cancer
- **JNJ-9530** — Hematological Malignancies
- **JNJ-9892** — Hematological Malignancies
- **JNJ-9968** — Hematological Malignancies
- **macitentan** — Pulmonary Arterial Hypertension 75mg — Trial/Program: UNISUS — Partner: Nippon Shinyaku
- **milvexian** — Acute Coronary Syndrome — Partner: Bristol Myers Squibb
- **milvexian** — Atrial Fibrillation — Partner: Bristol Myers Squibb
- **milvexian** — Secondary Stroke Prevention — Partner: Bristol Myers Squibb
- **nipocalimab** — Chronic Inflammatory Demyelinating Polyneuropathy — Trial/Program: ARISE
- **nipocalimab** — Fetal and Neonatal Alloimmune Thrombocytopenia — Trial/Program: FREESIA
- **nipocalimab** — Hemolytic Disease of the Fetus and Newborn — Trial/Program: AZALEA
- **nipocalimab** — Idiopathic Inflammatory Myopathy
- **nipocalimab** — Sjogren's Disease
- **nipocalimab** — Systemic Lupus Erythematosus
- **nipocalimab** — Warm Autoimmune Hemolytic Anemia — Trial/Program: ENERGY
- **pasritamig** — Prostate Cancer
- **posdinemab** — Alzheimer's Disease — Trial/Program: AUTONOMY
- **RPGR Gene Therapy** — Retinitis Pigmentosa — Trial/Program: LUMEOS — Partner: UCL Business Plc
- **RYBREVANT (amivantamab)** — Colorectal Cancer — Trial/Program: ORIGAMI-2
- **RYBREVANT (amivantamab)** — Colorectal Cancer 2L — Trial/Program: ORIGAMI-3
- **RYBREVANT (amivantamab)** — Frontline Non Small Cell Lung Cancer in combination with chemotherapy — Trial/Program: PAPILLON
- **RYBREVANT (amivantamab)** — Non Small Cell Lung Cancer — Trial/Program: PALOMA-3
- **seltorexant** — Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms — Trial/Program: OARS
- **SIMPONI (golimumab)** — Partner: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation
- **SIRTURO** — Leprosy
- **SIRTURO** — Tuberculosis Long Acting
- **SPRAVATO (esketamine)** — Major Depressive Disorder with Suicidal Ideation Pediatrics
- **SPRAVATO (esketamine)** — Treatment Resistant Depression monotherapy — Trial/Program: TRD4005
- **STELARA (ustekinumab)**
- **STELARA (ustekinumab)** — Pediatric Ulcerative Colitis — Trial/Program: UNIFI JR
- **TALVEY (talquetamab)** — Relapsed Refractory Multiple Myeloma A-CD38 Naïve — Trial/Program: MonumenTAL-3
- **TALVEY (talquetamab)** — Relapsed Refractory Multiple Myeloma CD38 exposed — Trial/Program: MonumenTAL-6
- **TALVEY + TECVAYLI** — Relapsed Refractory Multiple Myeloma — Trial/Program: RedirecTT-1
- **TALVEY + TECVAYLI** — Relapsed Refractory Multiple Myeloma CD38 exposed — Trial/Program: MonumenTAL-6
- **TAR-210 (RIS/erdafitinib)** — Intravesical Delivery System for Localized Bladder Cancer — Trial/Program: MoonRISe-1
- **TECVAYLI (teclistamab)** — Multiple Myeloma 1-3PLs — Trial/Program: MajesTEC-3
- **TECVAYLI (teclistamab)** — Relapsed Refractory Multiple Myeloma CD38 exposed — Trial/Program: MajesTEC-9
- **TECVAYLI (teclistamab)** — TE NDMM maintenance — Trial/Program: MajesTEC-4
- **TECVAYLI (teclistamab)** — TIE NDMM in combination with DR — Trial/Program: MajesTEC-7
- **TREMFYA (guselkumab)** — Partner: MorphoSys AG
- **TREMFYA (guselkumab)** — Pediatric Crohn's Disease — Trial/Program: MACARONI-23 — Partner: MorphoSys AG
- **UPTRAVI (selexipag)** — Pediatric Pulmonary Arterial Hypertension — Trial/Program: SALTO — Partner: Nippon Shinyaku

## Removed / Discontinued items
_None detected._

## Phase changes
_None detected._

## Citations
- https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Previous snapshot file: snapshots/jnj/latest.json
